Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Queensland Health
Baxter
Argus Health
Farmers Insurance
Accenture

Generated: August 24, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,250,419

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,250,419 protect, and when does it expire?

Patent 7,250,419 protects BRILINTA and is included in one NDA.

This patent has eighty-five patent family members in thirty-four countries.

Summary for Patent: 7,250,419
Title:Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition
Abstract: The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.
Inventor(s): Hardern; David (Sutton Bonington, GB), Ingall; Anthony (Loughborough, GB), Springthorpe; Brian (Loughborough, GB), Willis; Paul (West Bridgford, GB), Guile; Simon (Loughborough, GB)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:11/230,493
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,250,419
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 7,250,419

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astrazeneca Pharms BRILINTA ticagrelor TABLET;ORAL 022433-002 Sep 3, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF MYOCARDIAL INFARCTION ➤ Sign Up
Astrazeneca Pharms BRILINTA ticagrelor TABLET;ORAL 022433-002 Sep 3, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y Y REDUCTION OF THE RATE OF THROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME ➤ Sign Up
Astrazeneca Pharms BRILINTA ticagrelor TABLET;ORAL 022433-002 Sep 3, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF STABLE AND UNSTABLE ANGINA ➤ Sign Up
Astrazeneca Pharms BRILINTA ticagrelor TABLET;ORAL 022433-002 Sep 3, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y Y METHOD OF INHIBITING PLATELET AGGREGATION ➤ Sign Up
Astrazeneca Pharms BRILINTA ticagrelor TABLET;ORAL 022433-002 Sep 3, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y Y REDUCTION OF THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION ➤ Sign Up
Astrazeneca Pharms BRILINTA ticagrelor TABLET;ORAL 022433-002 Sep 3, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF THROMBOTIC STROKE ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 7,250,419

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 023920 ➤ Sign Up
Argentina 058967 ➤ Sign Up
Argentina 072756 ➤ Sign Up
Austria 261970 ➤ Sign Up
Austria 418547 ➤ Sign Up
Austria 513816 ➤ Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Cantor Fitzgerald
Argus Health
Mallinckrodt
QuintilesIMS
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.